Compare Stryker Corporation (SYK) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Stryker Corporation vs 10X Genomics Inc — how do they compare? Stryker Corporation trades at $344.68 (market cap $133.54B), while 10X Genomics Inc trades at $57.31 (market cap $7.61B). The key difference: Stryker Corporation is far larger — about 17.5× 10X Genomics Inc's market cap, and Stryker Corporation pays a 1.01% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| SYK | TXG | |
|---|---|---|
Market Cap | $133.54B | $7.61B |
Sector | Technology | Health |
52-Week High | $394.34 | $58.57 |
52-Week Low | $282.58 | $11.34 |
Enterprise Value | $145.01B | $7.14B |
Dividend Yield | 1.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Stryker (SYK) trades at $341.17, down 1.34% on the day, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $379.44. The company reported strong Q2 2026 results with a 9% organic sales growth and an EPS beat, recovering from a Q1 cyber incident. Profitability remains robust with a net income margin of 14.43% and a dividend yield supported by recent increases.
The stock offers upside potential driven by earnings momentum and product innovation like Mako RPS, but risks include competitive pressures and past cybersecurity disruptions. Analyst sentiment is strongly bullish with 74% buy ratings, though valuation multiples like a P/E of 36.08 suggest premium pricing relative to historical norms.
TXG trades at $58.57, up 12.57% in 24 hours, reflecting strong momentum. The stock is technically bullish with moving averages supporting the uptrend, though RSI levels suggest overbought conditions. Fundamentally, the company shows improving trends with Q2 2026 earnings beating estimates and revenue growth, yet remains unprofitable with a negative net income margin. Recent news highlights collaborations and acquisitions expanding its genomic capabilities.
Outlook is mixed; analyst consensus is neutral with a $46 price target below current levels, indicating caution despite recent beats. Key risks include sustained losses and competitive pressures, but operational cash flow growth and strategic expansions offer potential upside for patient investors focused on long-term biotech innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
